Traws Pharma (TRAW) 10-Q2020 Q3 Quarterly report

Filed: 16 Nov 20, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: acquired, administered, AKT, AMPK, antiproliferative, apoptotic, arrest, await, BARDA, Biomedical, Blachly, caspase, characterize, Chen, childhood, colorectal, comparison, complimentary, congenital, crucial, Cui, cytostatic, cytotoxic, cytotoxicity, daily, deleted, destabilization, displayed, Divakar, dysregulation, emergence, emerging, energy, Engel, equivocal, exhaustion, exhibited, exposure, family, FIH, Finn, formation, gastric, gastrointestinal, gene, glioblastoma, Hazard, healing, hepatocellular, highest, hormonal, Hortobagyi, importantly, inactivation, induce, induced, induction, inherited, insensitive, interval, invasion, killing, kinase, Knudsen, Kusakai, Kusaki, landlord, led, left, lethal, linked, Liu, lose, Lu, malignant, manner, mantle, MAPK, migration, mitotic, monolactate, multi, multidrug, multiple, murine, myc, myeloma, myelosuppression, neuroblastoma, newly, nM, Notable, NSCLC, ovarian, overexpressing, overexpression, PARP, partnership, PC, PDGFR, Perumal, Phippen, phosphorylation, poor, potent, preliminary, presence, prolonged, promoting, rational, rb, receptor, Reddy, remeasured, renal, renew, renewed, resistance, resistant, retinoblastoma, senescence, sensitivity, Silverman, Sledge, slightly, spectrum, Spring, step, substrate, suitable, Suzuki, thought, toxicity, triple, uncommon, unmet, unsuccessful, viability, visceral, wide, wound

Removed: accelerated, achieving, acute, adaptive, additionally, adult, advance, AEs, age, Agency, allogenic, America, AML, anaemia, analyze, analyzing, animal, anticipate, approach, ASH, assessment, biomarker, blinded, blocking, bone, charge, chemistry, circulating, cohort, commence, commonly, constipation, continuation, conventional, CR, decitabine, defining, Department, diarrhea, discontinuation, DMC, domain, dysuria, education, effort, EHA, elevated, eligibility, eligible, EMA, enroll, entry, escalation, establish, ethical, eukaryotic, European, evaluable, evidence, expanded, expansion, exploratory, explored, extensive, factor, fatigue, feasible, featured, febrile, feedback, female, final, finance, frequent, frequently, futility, genomic, geographical, governing, healthy, hematologic, Hematology, hematopoietic, hematuria, highlighted, identified, implemented, improve, incurable, independence, Independent, integral, Intermediate, intracellular, investigational, ITT, IWG, label, lead, lessee, leukemic, leukopenia, lot, low, male, marrow, median, mediated, methylation, modified, Myeloid, narrow, nausea, NCE, nivolumab, Opportunity, optional, ORR, outlined, participating, path, pattern, periodic, peripheral, permitting, pivotal, pneumonia, PR, practical, predict, presentation, presented, proceed, produce, Prognostic, prospectively, protocol, purposely, pyrexia, radiation, raf, RASopathiesNet, RBD, RDEB, reach, recognize, red, refined, regulated, relying, remedial, Remission, represented, responded, rest, restatement, retrospective, Revised, SAE, sample, SAP, SCC, schedule, Scoring, screening, selection, selective, sequential, sequentially, shortfall, side, SPA, stage, statistical, stem, stringent, submit, termed, test, thrombocytopenia, transformation, transfusion, transition, translation, transplant, twelve, Type, undertaken, unknown, updated, urinary, VHR, white, workforce

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated TRAW transcripts

TRAW similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Onconova Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven Fruchtman, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. That information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 16, 2020

/s/ Steven M. Fruchtman, M.D.

Steven M. Fruchtman, M.D.

President and Chief Executive Officer

( Principal Executive and Principal Operating Officer )

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.